Codexis(US:CDXS)2026-03-11 21:30Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [20] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [20] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, an increase from 56% in the prior year [20][21] - Net income for Q4 2025 was $9.6 million, compared to a loss of $10.4 million in Q4 2024, while the net loss for the full year 2025 was $44 million, down from $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin in 2025, with stabilization in revenue expected to fuel growth for the next 3-5 years [9] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling up production to 100 grams, with plans to reach half a kilo by the end of 2026 [5][6] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in RNA medicine is estimated to be $2 billion in five years, with a growing demand for siRNA medicines at a rate of 5%-10% per year [4][5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [55] Company Strategy and Development Direction - The company aims to establish itself as a key technology provider in the RNA medicine market, focusing on the ECO Synthesis platform to address production challenges [4][5] - Plans for 2026 include scaling up the ECO Synthesis manufacturing platform, achieving half-kilogram scale, and beginning construction of a GMP facility to support customer needs [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for siRNA therapeutics and the company's ability to meet this demand through innovative technology [55] - The company anticipates that 2026 will be a year of significant progress, with a revenue target of $72 million to $76 million, and expects to maintain stable gross margins [25][27] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value for stereoisomer control - Management is actively exploring the biological activity of stereo configurations generated by the ECO Synthesis platform and plans to present data at the TIDES USA meeting [31][32] Question: Understanding the recent announced deal - The recent deal involves a small organization with a cardiovascular asset, and discussions have been ongoing for many months to address their manufacturing challenges [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, and if successful, the company will progress to IND submissions and potentially commercial agreements for larger quantities [41][43] Question: Revenue guidance visibility - Management indicated that a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, with some speculative elements due to the early part of the year [49][50] Question: Industry demand for siRNA - Management noted that the siRNA therapeutic pipeline is vibrant, with a growing number of assets in clinical trials, projecting a significant increase in demand by 2030 [53][55] Question: Revenue mix and growth expectations - The company expects growth to primarily come from the ECO side of the business, while the small molecule biocatalysis business is expected to stabilize and contribute to growth over the next few years [60][63]